

## DAFTAR PUSTAKA

- Agarwal, A. Nath, K. A. (2020). Chapter 18 - Pathophysiology of Chronic Kidney Disease Progression: Organ and Cellular Considerations. In: Kimmel PL, Rosenberg ME, BT-CRD Second E. Academic Press, 263–278, <https://www.sciencedirect.com/science/article/pii/B9780128158760000188>
- Chen, T.K., Knicely, D.H., Grams, M.E. (2019). Chronic kidney disease diagnosis and management: a review. *Jama*, 322(13), 1294–1304.
- Cho, W.Y., Lim, S.Y., Yang, J.H., Oh, S.W., Kim, M.G., Jo, S.K. (2020). Urinary tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 as biomarkers of patients with established acute kidney injury. *Korean J Intern Med*, 35(3), 662–671.
- Costanzo, L., Soto, B., Meier, R., Geraghty, P. (2022). The Biology and Function of Tissue Inhibitor of Metalloproteinase 2 in the Lungs. *Kuwano K. Pulm Med*, 3632764. <https://doi.org/10.1155/2022/3632764>
- Emlet, D.R., Pastor-Soler, N., Marciszyn, A., Wen, X., Gomez, H., Humphries, I.V. (2017). Insulin-like growth factor binding protein 7 and tissue inhibitor of metalloproteinases-2: differential expression and secretion in human kidney tubule cells. *Am J Physiol Physiol*, 312(2), F284–296.
- Faguer, S., Piedrafita, A., Sanz, A. B., Siwy, J., Mina, I. K., Alves, M., Bousquet, P., Marcheix, B., Casemayou, A., Klein, J., Minville, V., Breuil, B., Ortiz, A., & Schanstra, J. P. (2024). Performances of acute kidney injury biomarkers vary according to sex. *Clinical Kidney Journal*, 17(5), 1–9. <https://doi.org/10.1093/ckj/sfae091>
- Fauci, A.S, Jameson, J.L., Kasper D. (2018). *Harrison's Principles of Internal Medicine 19th Edition*. New York, McGraw-Hill Education.
- Garcia-Fernandez, N, Jacobs-Cachá, C, Mora-Gutiérrez, J.M., Vergara, A., Orbe, J., Soler, M.J. (2020). Matrix metalloproteinases in diabetic kidney disease. *J Clin Med*,9(2), 472.
- Garcia, G. G., Iyengar, A., Kaze, F., Kierans, C., Padilla-Altamira, C., & Luyckx, V. A. (2022). Sex and gender differences in chronic kidney disease and access to care around the globe. *ELSEVEIRIR*. <https://doi.org/10.1016/j.semnephrol.2022.04.001>
- Gupta, A., Sontakke, T., Acharya, S., & Kumar, S. (2024). A Comprehensive Review of Biomarkers for Chronic Kidney Disease in Older Individuals: Current Perspectives and Future Directions. *Cureus*, 16(9). <https://doi.org/10.7759/cureus.70262>

- Hirata, T., Fan, F., Fan, L., Amin, G., White, T., Geurts, A.M. (2022). Knockout of matrix metalloproteinase 2 opposes hypertension-and diabetes-induced nephropathy. *J Cardiovasc Pharmacol*, 10–1097.
- Hustrini, N.M., Susalit, E., Rotmans, J.I. (2022). Prevalence and risk factors for chronic kidney disease in Indonesia: An analysis of the National Basic Health Survey 2018. *J Glob Health*, 12, 4074.
- Jameson, J., Fauci, A., Kasper, D., Hauser, S., Longo, D., Loscalzo, J. (2018). *Harrison's Principles of Internal Medicine* 20th ed. New York NY, McGraw Hill Educ.
- Johnson, A.C.M., Zager, R.A. (2018). Mechanisms and consequences of oxidant-induced renal preconditioning: an Nrf2-dependent, P21-independent, anti-senescence pathway. *Nephrol Dial Transplant*, 33(11), 1927–1941.
- Kadatane, S.P., Satariano, M., Massey, M., Mongan, K., Raina, R. (2023). The role of inflammation in CKD. *Cells*, 12(12), 1581.
- KDIGO CKD Work Group. (2013). *KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease*. New York.
- Kobayashi, A., Hirano, K., Okuda, T., Ikenoue, T., Yokoo, T., & Fukuma, S. (2025). Estimating the prevalence of chronic kidney disease in the older population using health screening data in Japan. *Clinical and Experimental Nephrology*, 29(3), 276–282. <https://doi.org/10.1007/s10157-024-02570-y>
- Kobusiak-Prokopowicz, M., Kaaz, K., Marciniak, D., Karolko, B., Mysiak, A. (2021). Relationships between Circulating Matrix Metalloproteinases, Tissue Inhibitor TIMP-2, and Renal Function in Patients with Myocarditis. *Kidney Blood Press Res*, 46(6), 749–757. <https://doi.org/10.1159/000519594>
- Kovesdy, C. P. (2022). Epidemiology of chronic kidney disease: an update 2022. *Kidney International Supplements*, 12(1), 7. <https://doi.org/10.1016/J.KISU.2021.11.003>
- Ntrinas, T., Papatotiriou, M., Balta, L., Kalavrizioti, D., Vamvakas, S., Papachristou, E. (2019). Biomarkers in Progressive Chronic Kidney Disease. Still a Long Way to Go. *PRILOZI*, 40(3), 27–39. <https://doi.org/10.2478/prilozi-2020-0002>
- Poznyak, A. V., Sadykhov, N. K., Kartuesov, A. G., Borisov, E. E., Sukhorukov, V. N., & Orekhov, A. N. (2022). Atherosclerosis Specific Features in Chronic Kidney. *Biomedicines*, 1–14.
- Topf, J.M., Inker, L.A. (2019). CHAPTER 3 - Measurement of glomerular filtration rate. Elsevier, 22–9. <https://www.sciencedirect.com/science/article/pii/B9780323478717000125>

- Schanz, M., Kimmel, M., Alscher, M. D., Amann, K., & Daniel, C. (2023). *TIMP-2 and IGFBP7 in human kidney biopsies in renal disease*. 16(9), 1434–1446. <https://doi.org/10.1093/ckj/sfad010>
- Strau, C., Booke, H., Forni, L., & Zarbock, A. (2024). Biomarkers of acute kidney injury: From discovery to the future of clinical practice. *Journal of Clinical Anesthesia*, 95(April). <https://doi.org/10.1016/j.jclinane.2024.111458>
- Wen, X., Zhang, J., Wan, X., Frank, A.A., Qu, X., Kellum, J.A. (2020). Tissue Inhibitor of Metalloproteinases-2 Mediates Kidney Injury during Sepsis. *Nephron*, 144(12), 644–649. <https://doi.org/10.1159/000511165>
- Yanti, A. K. E., Mamile, R., Hidayati, P. H., Dwimartyono, F., & Sanna, A. T. (2022). Karakteristik Pasien Penyakit Ginjal Kronik di Rumah Sakit Ibnu Sina Makassar Tahun 2019-2021. *Wal'afiat Hospital Journal*, 03(02), 126–138.
- Zakiyanov, O., Kalousová, M., Zima, T., Tesař, V. (2021). Matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in kidney disease. *Adv Clin Chem*, 105, 141–212.
- Zhang, W. R., & Parikh, C. R. (2019). Biomarkers of Acute and Chronic Kidney Disease. *Annu Rev Physiol*. <https://doi.org/10.1146/annurev-physiol-020518-114605>.Biomarkers